INVO Bioscience (INVO) Tops Q2 EPS by 14c

INVO Bioscience (NASDAQ: INVO) reported Q2 EPS of ($3.06), $0.14 better than the analyst estimate of ($3.20). Revenue for the quarter came in at $315.9 thousand versus the consensus estimate of $517 thousand.

For earnings history and earnings-related data on INVO Bioscience (INVO) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Jefferies Financial Group (JEF) Misses Q2 EPS by 22c
• Qualcomm expects $40bn in non-handset revenue by fiscal 2029